Will US, Europe work together on AI regulation?

Michael Walter | | Health Exec | Policy & Regulations
Globe

Sundar Pichai, who serves as the CEO for both Alphabet and Google, wants the United States and European Union to work together on developing AI regulations. Is there any chance such cooperation will occur?

As reported by Fortune, Pichai said “there is no question in my mind that artificial intelligence needs to be regulated” and shared his hope that guidelines would balance “potential harms with social opportunities.”

A.I. needs to be regulated: Google CEO calls for coordinated U.S.-EU rules

In the past, the United States has pushed to develop its own AI guidelines without minimal input from other countries. In addition, the White House recently shared a new set of principles for governing AI development solutions, pushing for a limited regulatory approach and the use of fair, unbiased algorithms. The EU is expected to share its own plans for legislating AI in the near future.

Click the link below for the full story from Fortune:

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

Senate Judiciary Chair demands UnitedHealth turn over Medicare records
VA releases another 1,400 employees as FDA invites 300 back to work
UnitedHealthcare sued by 17 hospitals in $145M dispute over out-of-network reimbursement
Report: UnitedHealth under investigation by DOJ for Medicare Advantage upcoding
FDA approves first therapy for very rare lipid storage disorder
FDA announces Class I recall of Boston Scientific pacemakers—replacement may be necessary

Around the web

Cardiovascular Business
American Heart Association highlights importance of NIH as battle over Trump funding cuts continues

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

Cardiovascular Business
Cardiologist questions FDA’s approval process for high-risk medical devices

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

Cardiovascular Business
FDA announces new recall of Johnson & Johnson heart pumps over safety concerns

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”